Biomarin Pharmaceutical Inc (BMRN)
Financial leverage ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 6,988,940 | 6,851,200 | 7,067,120 | 6,872,670 | 6,841,600 | 6,758,160 | 6,563,170 | 6,433,700 | 6,375,070 | 6,264,040 | 6,145,840 | 6,062,710 | 6,004,770 | 5,977,480 | 5,898,500 | 5,805,050 | 5,848,020 | 6,158,090 | 5,302,110 | 4,722,840 |
| Total stockholders’ equity | US$ in thousands | 5,657,990 | 5,413,400 | 5,286,300 | 5,073,820 | 4,951,550 | 4,896,900 | 4,782,830 | 4,659,040 | 4,603,160 | 4,568,510 | 4,499,740 | 4,386,240 | 4,265,670 | 4,261,080 | 4,236,500 | 4,162,010 | 4,100,930 | 4,053,890 | 3,236,680 | 3,239,960 |
| Financial leverage ratio | 1.24 | 1.27 | 1.34 | 1.35 | 1.38 | 1.38 | 1.37 | 1.38 | 1.38 | 1.37 | 1.37 | 1.38 | 1.41 | 1.40 | 1.39 | 1.39 | 1.43 | 1.52 | 1.64 | 1.46 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $6,988,940K ÷ $5,657,990K
= 1.24
The financial leverage ratio of Biomarin Pharmaceutical Inc has shown a fluctuating trend over the past few years. The ratio was 1.46 as of March 31, 2020, indicating that the company had $1.46 in debt for every dollar of equity. It increased to 1.64 by June 30, 2020, but then decreased to 1.43 by December 31, 2020.
From March 31, 2021, to June 30, 2022, the ratio remained relatively stable between 1.39 and 1.37, signaling a consistent level of leverage. However, there was a slight increase to 1.38 by December 31, 2022. Subsequently, the ratio fluctuated between 1.34 and 1.38 until December 31, 2024, when it decreased to 1.24.
Overall, the financial leverage ratio of Biomarin Pharmaceutical Inc suggests that the company has maintained a moderate level of debt relative to its equity, with some variability in leverage levels over the analyzed period. Investors and creditors may use this ratio to assess the company's financial risk and its ability to meet its debt obligations.
Peer comparison
Dec 31, 2024